Search Results

You are looking at 11 - 20 of 486 items for :

  • "locally advanced" x
  • Refine by Access: All x
Clear All
Full access

Eric H. Bent, Eric Wehrenberg-Klee, Eugene J. Koay, Lipika Goyal, and Jennifer Y. Wo

the management of locally advanced HCC, with local control rates ranging from 87% to 100% at 1 year and OS in the range of 60% to 69% at 2 years in phase II studies. 14 , 15 One recent phase II study of SBRT that included patients with tumors up to 12

Full access

Clayton A. Smith and Lisa A. Kachnic

Despite this improvement, patients with locally advanced rectal cancer (LARC; commonly defined as T3 or T4 primary or nodal metastases) still had unacceptably high risks of local and distant failure relative to those with early-stage disease. Therefore

Full access

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz

Modern therapy for locally advanced rectal cancer (LARC), with the combination of preoperative chemoradiotherapy and improved surgical techniques, has led to significant improvements in local disease control. Distant recurrence rates now exceed

Full access

Joshua B. Brown, Reetesh K. Pai, Melissa A. Burgess, Jennifer Chennat, and Amer H. Zureikat

describes a patient with locally advanced gastric GIST harboring a KIT exon 11 mutation who experienced a near-pCR to neoadjuvant imatinib. Case Presentation A 71-year-old woman with a medical history of chronic obstructive pulmonary disease on 3

Full access

Marsha Reyngold, Joyce Niland, Anna ter Veer, Dana Milne, Tanios Bekaii-Saab, Steven J. Cohen, Lily Lai, Deborah Schrag, John M. Skibber, William Small Jr, Martin Weiser, Neal Wilkinson, and Karyn A. Goodman

Preoperative chemoradiation followed by surgical resection has been the standard of care in the management of locally advanced rectal cancer. Patients with T3-T4 or node-positive disease have a significant risk of both local and distant failure

Full access

Luis Aguirre, Jacques Fontaine, Jessica Frakes, Sarah Hoffe, Jose Pimiento, and Rutika Mehta

Background: The standard of care for locally advanced esophageal cancer is chemoradiation followed by surgery. Age and obesity are risk factors for both esophageal cancer and cardiovascular diseases. In this study, we explored whether the presence

Full access

Martha Isabel Junio Parroco and Genalin Fabul Amparo

Recurrence of cervical cancer is one of the most important and significant discussions in Gynecologic Oncology especially in patients with locally advanced stage. The over-all goal of this study is to detect over-all recurrence and survival rate for

Full access

Katherine Y. Fan, Avani S. Dholakia, Aaron T. Wild, Zheng Su, Amy Hacker-Prietz, Rachit Kumar, Mary Hodgin, Charles C. Hsu, Dung T. Le, Ana De Jesus-Acosta, Luis A. Diaz Jr, Daniel A. Laheru, Ralph H. Hruban, Elliot K. Fishman, Todd D. Brown, Timothy M. Pawlik, Christopher L. Wolfgang, Phuoc T. Tran, and Joseph M. Herman

), borderline resectable/locally advanced (BL), or metastatic (M) pancreatic cancer, or BPD. Diagnoses considered to be benign disease included autoimmune pancreatitis, intraductal papillary mucinous neoplasm, or pancreatic cyst. Exclusion criteria included

Full access

Helmneh M. Sineshaw, K. Robin Yabroff, V. Liana Tsikitis, Ahmedin Jemal, and Timur Mitin

with locally advanced rectal cancer (LARC) in the United States using data from the National Cancer Database (NCDB). 8 Patients who received concurrent chemoradiation therapy without surgery had lower survival rates. 8 Others, however, used

Full access

Cole Friedes, Nick Mai, Wei Fu, Peijin Han, Ranh Voong, and Russell Hales

with de novo locally advanced NSCLC (LA-NSCLC). Herein, we present outcomes of patients with iLR vs. LA-NSCLC treated with definitive therapy. Methods: Patients with NSCLC treated with definitive radiotherapy between 2008–2018 at a tertiary academic